BioSpace News Archive

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at two upcoming investment conferences

Satsuma Pharmaceuticals, Inc. announced that it will be presenting two posters at the 19th Congress of the International Headache Society convening at the Convention Centre Dublin in Dublin, Ireland from the 5th to the 8th of September 2019.

Lineage Cell Therapeutics, Inc. announced that its paper entitled “Transplantation of Human Embryonic Stem Cell Derived Retinal Tissue in the Subretinal Space of the Cat Eye,” (Singh et al.), has been selected for publishing and will be featured on the cover of the September 2019 issue of Stem Cells and Development Journal, Volume 28, Number 17.

BELLUS Health Inc., announced the filing of a preliminary prospectus supplement to its short form base shelf prospectus dated July 26, 2019 in connection with a proposed US$60 million public offering of its common shares, and the filing of an application to list its common shares on the Nasdaq Global Market in the United States under the ticker “BLU”.

Infinity a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma

Related patents granted in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia; Patents pending in Brazil and other countries

H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10 at 12:30 pm ET. The conference is being held September 8-10 at the Lotte New York Palace Hotel.

PainShield Added to Federal Supply Schedule through Marathon Medical, Providing Opioid Alternative Pain Management System

We have completed over 33 studies ranging in size from a single hood, to an entire aseptic manufacturing line, we have over 5,500 hours of combined experience in the planning, development and execution/documentation of these studies.